Dr Laborda is the Associate Director of Immuno Oncology at Calibr, a division of Scripps Research, a non-profit research organization focused on addressing unmet needs through novel therapeutic approaches. He received a BS in Veterinary Medicine and a PhD in Biochemistry, Molecular Biology, and Biomedicine from Universidad Autonoma de Barcelona. His PhD focused on developing tumor selective Oncolytic Adenoviruses with enhanced potency for canine patients. This work lead to treating canine cancer patients under compassionate use with significant clinical responses, and informed on the human clinical trial run years later with a human version of a similar Oncolytic Adenovirus. After completing his PhD he joined Genelux Corporation for an Internship and later Calibr as a Postdoctoral Researcher where he has been part of the team developing the Universal “Switchable” CAR-T Cell Platform. The platform was partnered with AbbVie later on and is being investigated in the clinic for CD19 positive malignancies. Moreover, this team is exploring the potential application of the switchable CAR-T cells for solid tumors.